30/05/2026
"The Prosigna test, made by the global diagnostics company Veracyte, analyses the activity of 50 genes in tumour tissue. It determines the molecular subtype and provides a score revealing the risk of breast cancer returning in the next decade, helping doctors decide if chemotherapy is worthwhile or not.
The randomised trial involved 4,429 patients aged 40 or above with hormone-positive breast cancer. This is the most common form of breast cancer, accounting for up to 80% of breast cancer cases globally."
https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy
Trial suggests patients with a low test score could be treated with hormone therapy alone with near-identical outcomes